The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
The Surveillance, Epidemiology, and End Results (SEER) Program and Pathology: Toward Strengthening the Critical Relationship
Open accessAbstract
The Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute collects data on cancer diagnoses, treatment, and survival for approximately 30% of the United States (US) population. To reflect advances in research and oncology practice, approaches to cancer control are evolving from simply enumerating the development of cancers by organ site in populations to including monitoring of cancer occurrence by histopathologic and molecular subtype, as defined by driver mutations and other alterations. SEER is an important population-based resource for understanding the implications of pathology diagnoses across demographic groups, geographic regions, and time and provides unique insights into the practice of oncology in the US that are not attainable from other sources. It provides incidence, survival, and mortality data for histopathologic cancer subtypes, and data by molecular subtyping are expanding. The program is developing systems to capture additional biomarker data, results from special populations, and expand biospecimen banking to enable cutting-edge cancer research and oncology practice. Pathology has always been central and critical to the effectiveness of SEER, and strengthening this relationship in this modern era of cancer diagnosis could be mutually beneficial. Achieving this goal requires close interactions between pathologists and the SEER program. This review provides a brief overview of SEER, focuses on facets relevant to pathology practice and research, and highlights the opportunities and challenges for pathologists to benefit from and enhance the value of SEER data.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Early detection, diagnosis, and treatment are crucial to the survival outcomes of esophageal cancer, and the 5-year survival rate of early-stage patients can exceed 95% [6].”
From Symptom Experiences before Medical Help-Seeking and Psychosocial Responses of Patients with Esophageal Cancer: A Qualitative Study. (2023) · cites this paper as [6]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Swerdlow, S. H., Campo, E., Pileri, S. A., Harris, N. L., Stein, H., Siebert, R., Advani, R., Ghielmini, M., Salles, G. A., Zelenetz, A. D., et al. (2016) · Blood · doi:10.1182/blood-2016-01-643569 · Cited by 7,831
Gail, M. H., Brinton, L. A., Byar, D. P., Corle, D. K., Green, S. B., Schairer, C., & Mulvihill, J. J. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.24.1879 · Cited by 3,334
US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status
Howlader, N., Altekruse, S. F., Li, C. I., Chen, V. W., Clarke, C. A., Ries, L. A. G., & Cronin, K. A. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju055 · Cited by 1,572
Self-citationLindeman, N. I., Cagle, P. T., Beasley, M. B., Chitale, D. A., Dacic, S., Giaccone, G., Jenkins, R. B., Kwiatkowski, D. J., Saldivar, J.-S., Squire, J., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318290868f · Cited by 1,280
The Decrease in Breast-Cancer Incidence in 2003 in the United States
Ravdin, P. M., Cronin, K. A., Howlader, N., Berg, C. D., Chlebowski, R. T., Feuer, E. J., Edwards, B. K., & Berry, D. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmsr070105 · Cited by 981
Lindeman, N. I., Cagle, P. T., Beasley, M. B., Chitale, D. A., Đačić, S., Giaccone, G., Jenkins, R. B., Kwiatkowski, D. J., Saldivar, J., Squire, J. A., et al. (2013) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2013.03.001 · Cited by 461
Albain, K. S., Unger, J. M., Crowley, J. J., Coltman, C. A., & Hershman, D. L. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp175 · Cited by 458
Cervical Cancer Trends in the United States: A 35-Year Population-Based Analysis
Adegoke, O. O., Kulasingam, S., & Virnig, B. A. (2012) · Journal of Women s Health · doi:10.1089/jwh.2011.3385 · Cited by 353
Descriptive epidemiology of dermatofibrosarcoma protuberans in the United States, 1973 to 2002
Criscione, V. D., & Weinstock, M. A. (2006) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2006.09.006 · Cited by 350
Breast Cancer Risk in Relation to the Interval Between Menopause and Starting Hormone Therapy
Beral, V., REEVES, G. K., Bull, D., Green, J., & Collaborators, F. T. M. W. S. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq527 · Cited by 290
Cited by
Sorted by citations
Zhou, Y., Yang, D., Yang, Q., Lv, X., Huang, W., Zhou, Z., Wang, Y., Zhang, Z., Yuan, T., Ding, X., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-20059-6 · Cited by 672
Ward, E., Sherman, R., Henley, S. J., Jemal, A., Siegel, D. A., Feuer, E. J., Firth, A. U., Kohler, B., Scott, S., Ma, J., et al. (2019) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djz106 · Cited by 324
Blackford, A. L., Canto, M. I., Klein, A. P., Hruban, R. H., & Goggins, M. (2020) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djaa004 · Cited by 270
Atkinson, E. G., Maihofer, A. X., Kanai, M., Martin, A. R., Karczewski, K. J., Santoro, M. L., Ulirsch, J. C., Kamatani, Y., Okada, Y., Finucane, H. K., et al. (2021) · Nature Genetics · doi:10.1038/s41588-020-00766-y · Cited by 239
Zhang, L.-X., Gao, J., Long, X., Zhang, P., Yang, X., Zhu, S., Pei, X., Qiu, B., Chen, S., Lü, F., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01586-w · Cited by 149
Metadata
- Authors
- Duggan, M. A., Anderson, W. F., Altekruse, S., Penberthy, L., & Sherman, M. E.
- Affiliations
- University of Calgary (CA)
- Division of Cancer Epidemiology and Genetics (US)
- Cancer Control and Populations Sciences
- National Cancer Institute (US)
- Corresponding author
- Duggan, Máire A.
- Venue
- American Journal of Surgical Pathology
- Published
- 2016-12
- Volume
- 40
- Issue
- 12
- Pages
- e94-e102
- ISSN
- 0147-5185 (ISSN-L)
- PMC
- PMC5106320
- OpenAlex
- W2530755795
- Cited by
- 472
- References
- 46
- Citations by year
- 2026: 28 · 2025: 49 · 2024: 72 · 2023: 60 · 2022: 73 · 2021: 62 · 2020: 78 · 2019: 42 · 2018: 6 · 2017: 1
- FWCI
- 1.64
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The American Journal of Surgical Pathology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (Z99 CA999999)
- Topics
- Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Oncology › Cancer Diagnosis and Treatment
- Keywords
- cancer pathology, histological subtypes, molecular subtypes, driver mutations, cancer incidence, cancer survival, cancer mortality, biomarker data, cancer control
- MeSH terms
- Humans, Medical Oncology, Neoplasms, Pathology, Clinical, Biomarkers, Tumor, United States, SEER Program, Interdisciplinary Communication, Pathology, Molecular
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
